All In Biotech

Drug Trial Radar · NCT07285122

Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

A Phase 1a/1b, Randomised, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RB042 Administered Via Inhalation to Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Feb 16, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Atisama TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.

Conditions

  • Healthy
  • Healthy Smoker
  • COPD (Chronic Obstructive Pulmonary Disease)
  • COPD

Interventions

  • RB042Drug

    A single or multiple doses of RB042 will be administered via a nebuliser.

  • Placebo inhalation solutionDrug

    A single or multiple doses of placebo will be administered via a nebuliser.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and frequency of treatment-emergent adverse events (TEAEs)Time frame: From Day 1 until the end of the study (Day 85 for Part A; Day 106 for Parts B and D)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.